© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
November 18, 2022
Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.
November 17, 2022
The results show serum IgA-IgG immune complex levels decreased in both patients treated with atacicept 25 mg ab atacicept 75 mg over time.
Ardelyx was issued a Complete Response Letter in July requestion an additional trial.
November 16, 2022
Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.
November 07, 2022
Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.
November 05, 2022
The treatment reduced UACR by 37.1% and LDLc by 17.12 compared to placebo.
Low sodium intake is considered less than 2.3 grams per day.
Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.
In a late-breaking abstract presented at ASN 2022, dapagliflozin attenuated the decline in eGFR between month 1-36 compared to placebo.
November 04, 2022
Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.
Atopic Dermatitis Severity Linked to Incremental Societal Healthcare Costs
Strong Response Maintenance for Plaque Psoriasis Patients Using Tildrakizumab
Clinical Efficacy, Safety of Brolucizumab Similar to Trial Results for nAMD Patients